Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05229562 · ClinicalTrials.gov registry record · Phase 1
A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 84
- Enrollment target
NCT05229562 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 84 participants.
The verdict
NCT05229562, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 84 participants
- Enrollment target
Study Summary
The study will be looking at an investigational drug, BIIB122, in healthy adult Japanese, Chinese, and Caucasian participants. The main goal of the study is to compare the drug level achieved in the body, between the different ethnic groups, after single and multiple doses of BIIB122. Researchers also want to see if single and multiple doses of BIIB122 are safe and if healthy participants can tolerate given doses of BIIB122.
Interventions
- DRUG BIIB122
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 84 participants |
| Start Date | 2022-02-17 |
| Est. Completion | 2022-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05229562
The ClinicalTrials.gov registry entry for NCT05229562 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 84 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIIB122 is the first listed.
NCT05229562 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05229562 about?
NCT05229562 is a clinical study titled "A Study to See How BIIB122 Works in the Human Body, and to Evaluate it's Safety, and Tolerability in Healthy Adult Japanese, Chinese, and Caucasian Participants". The study will be looking at an investigational drug, BIIB122, in healthy adult Japanese, Chinese, and Caucasian participants. The main goal of the study is to compare the drug level achieved in the body, between the different ethnic groups, after single and multiple doses of BIIB122. Researchers al...
What is the current status of trial NCT05229562?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 84 participants. The study started on 2022-02-17. Estimated completion is 2022-09-07.
What interventions are being tested in trial NCT05229562?
The interventions under investigation include: BIIB122 (DRUG).
Who is sponsoring clinical trial NCT05229562?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.